Publication

Video

Supplements and Featured Publications
Updates in NRG1+ Tumors

Dr. Liu on the Rationale for Examining Afatinib in NSCLC Harboring NRG1 Fusions

Author(s):

Stephen Liu, MD, discusses the rationale for examining afatinib in patients with non–small cell lung cancer harboring NRG1 fusions.

Stephen Liu, MD, an associate professor of medicine, director of thoracic oncology, and director of developmental therapeutics at Georgetown Lombardi Comprehensive Cancer Center, discusses the rationale for examining afatinib (Gilotrif) in patients with non–small cell lung cancer (NSCLC) harboring NRG1 fusions.

NRG1 fusions are different from other fusion events that occur in patients with NSCLC, as they don’t lead to a constitutively active kinase, Liu says. NRG1 is the ligand for the transmembrane receptor. The fusion brings the EGF-like domain of NRG1 into close proximity with its receptor, which is either ErbB3 or HER3. HER3 then tends to heterodimerize with HER2, although it could also do so with HER4, HER1 or EGFR, Liu explains.

Current strategies are focused on targeting receptors, as effective agents are already available, Liu notes. Afatinib is an orally bioavailable pan ErbB kinase that was developed to inhibit the abnormal signaling downstream of NRG1 fusion events, Liu concludes.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Benjamin Levy, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"